Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04085133
Other study ID # 12345817
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 26, 2019
Est. completion date April 1, 2020

Study information

Verified date September 2019
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree


Description:

Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree. The prevalence of bronchiectasis is age-related and occurs in every age group and in the pre-antibiotic era . it most often began in childhood. Recent evidence shows that bronchiectasis disproportionately affects women and older individuals and will be contributing to increase in healthcare burden.[3] International data show an increase in the prevalence of bronchiectasis over recent years.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date April 1, 2020
Est. primary completion date January 1, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - 1-patients were diagnosed to have tuberculosis by sputum culture and gene x pert. 2-patients were diagnosed to have bronchiectasis after lab and radiological examination as well as clinical score. 3- patients diagnosed as bronchiectasis after history of tuberculosis or anti Tuberculosis treatment with positive or negative tuberculous culture in the time of research. Exclusion Criteria: - 1-patients presented with other Pulmonary diseases. 2-Chronic liver and renal disease . 3- Lung cancer and tumors. 4- patients were previously diagnosed as bronchiectasis .

Study Design


Intervention

Diagnostic Test:
Gene Xpert Chest x ray and MSCT chest
Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis

Locations

Country Name City State
Egypt Assiut unviresty Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary To study prevalence of bronchiectasis in TB patients by case per year. How many patients of TB will be diagnosed as abronchiectasis One year
Secondary To evaluate the burden of bronchiectasis in TB patients by frequency of need for hospital admission per year, need for outpatient clinical visits per month and frequency of need for antimicrobial therapy other than anti-tuberculous treatment per month one year
See also
  Status Clinical Trial Phase
Recruiting NCT05017324 - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial N/A
Completed NCT04207112 - Economic Evaluation of New MDR TB Regimens Phase 2/Phase 3
Completed NCT04044001 - BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) Phase 1/Phase 2
Withdrawn NCT03159975 - Safety and Immunogenicity Study of GX-70 in TB Patient Phase 1
Completed NCT02984579 - Line Probe Assay Evaluation Study N/A
Completed NCT05568368 - Time-to-Detection in Culture of Mycobacterium Tuberculosis
Recruiting NCT04930978 - Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
Not yet recruiting NCT05477966 - A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
Completed NCT05097638 - Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
Active, not recruiting NCT05045391 - Pulmonary Aspergillosis in Tuberculosis Patients
Completed NCT02754765 - Evaluating Newly Approved Drugs for Multidrug-resistant TB Phase 3
Active, not recruiting NCT03896685 - Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Phase 3